• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    9/2/22 8:07:30 AM ET
    $ADMA
    $APM
    $AVEO
    $BLTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADMA alert in real time by email

     

    Gainers

    • bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 21.6% to $10.09 during Friday's pre-market session. The company's market cap stands at $40.4 million.
    • Biote (NASDAQ:BTMD) stock moved upwards by 14.51% to $5.05. The market value of their outstanding shares is at $38.2 million.
    • WAVE Life Sciences (NASDAQ:WVE) shares moved upwards by 13.94% to $3.35. The market value of their outstanding shares is at $290.8 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) stock increased by 10.94% to $5.27. The market value of their outstanding shares is at $126.1 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 9.89% to $1.42. The market value of their outstanding shares is at $38.0 million.
    • Belite Bio (NASDAQ:BLTE) stock moved upwards by 9.07% to $40.03. The company's market cap stands at $995.4 million.

    Losers

    • Caladrius Biosciences (NASDAQ:CLBS) stock decreased by 16.0% to $0.42 during Friday's pre-market session. The company's market cap stands at $25.4 million.
    • ADMA Biologics (NASDAQ:ADMA) stock fell 9.67% to $2.43. The market value of their outstanding shares is at $477.1 million.
    • AVEO Pharmaceuticals (NASDAQ:AVEO) stock declined by 9.34% to $7.58. The company's market cap stands at $262.3 million.
    • Kiromic BioPharma (NASDAQ:KRBP) shares declined by 9.29% to $0.38. The company's market cap stands at $6.0 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) stock decreased by 8.06% to $0.21. The market value of their outstanding shares is at $6.5 million.
    • Aptorum Gr (NASDAQ:APM) stock decreased by 7.59% to $1.34. The market value of their outstanding shares is at $47.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA
    $APM
    $AVEO
    $BLTE

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Wave Life Sciences Ltd.
    $WVE
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    Wave Life Sciences Ltd.
    $WVE
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    More analyst ratings

    $ADMA
    $APM
    $AVEO
    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

    CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the presentation can be accessed by visiting "Investor Events" on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this p

    2/23/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2025. Webcast InformationDate: Monday, March 2, 2026Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link: https://events.q4inc.com/attendee/547616305 Webcast Link InstructionsYou can join the live webcast by visiting

    2/23/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

    AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization. Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous syste

    2/19/26 8:30:00 AM ET
    $ALNY
    $DNLI
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADMA
    $APM
    $AVEO
    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    SEC Filings

    View All

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    2/18/26 6:01:56 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Belite Bio Inc

    SCHEDULE 13G/A - BELITE BIO, INC (0001889109) (Subject)

    2/17/26 4:30:28 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    2/12/26 4:06:04 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

    4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

    1/2/25 4:12:36 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 8,161 shares, decreasing direct ownership by 1% to 572,160 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    2/23/26 9:00:19 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Grossman Adam S covered exercise/tax liability with 24,793 shares, decreasing direct ownership by 1% to 2,259,586 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    2/23/26 9:00:18 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO and Treasurer Tade Brad L. covered exercise/tax liability with 6,479 shares, decreasing direct ownership by 3% to 232,940 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    2/23/26 9:00:18 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/29/21 5:44:34 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FOTIVDA

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/10/21 2:49:22 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    Leadership Updates

    Live Leadership Updates

    View All

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADMA Biologics Set to Join S&P SmallCap 600 Index

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

    9/17/24 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company's fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the

    2/19/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial

    2/18/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

    Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measur

    12/8/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $APM
    $AVEO
    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

    SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/12/24 1:34:17 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care